Dendritic cells loaded with apoptotic tumour cells induce a stronger T-cell response than dendritic cell-tumour hybrids in B-CLL

Leukemia

Volumn 17, Issue 5, 2003, Pages 894-899

  Kokhaei, P ^a   Rezvany, M R ^a   Virving, L ^a   Choudhury, A ^a   Rabbani, H ^a   Osterborg A ^a   Mellstedt, H ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Apoptotic tumour cells; B CLL; Dendritic cells; Hybrid cell; T cell

Indexed keywords

CYTOKINE; GAMMA INTERFERON; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ADOPTIVE IMMUNOTHERAPY; ADULT; AGED; ANTIGEN PRESENTING CELL; APOPTOSIS; ARTICLE; B CELL LEUKEMIA; B LYMPHOCYTE; CANCER IMMUNOTHERAPY; CANCER STAGING; CELL FUSION; CELL HYBRIDIZATION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RESPONSIVE ELEMENT; DENDRITIC CELL; ENDOCYTOSIS; FEMALE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN VITRO STUDY; INCUBATION TIME; INTERFERON PRODUCTION; LEUKEMIA CELL; LYMPHOCYTE PROLIFERATION; MALE; PRIORITY JOURNAL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR CELL;

EID: 0037851825     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402913     Document Type: Article

References (32)

1. Berger CL, Xu AL, Hanlon D, Lee C, Schechner J, Glusac E. Induction of human tumor-loaded dendritic cells. Int J Cancer 2001; 91: 438-447.
2. Banckereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YJ. Immunobiology of dendritic cells. Annu Rev Immunol 2000; 18: 767-811.
3. Biragyn A, Kwak LW. Designer cancer vaccines are still in fashion. Nat Med 2000; 6: 966-968.
4. Rezvany MR, Jeddi-Tehrani M, Rabbani H, Lewin N, Avila-Carino J, Osterborg A. Autologous T lymphocytes may specifically recognize leukaemic B cells in patients with chronic lymphocytic leukaemia. Br J Haematol 2000a; 111: 608-617.
5. Gong J, Chen D, Kashiwaba M, Kufe D. Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nat Med 1997; 3: 558-561.
6. Rovere P, Vallinoto C, Bondanza A, Crosti MC, Rescigno M, Ricciardi-Castagnoli P. Bystander apoptosis triggers dendritic cell maturation and antigen-presenting function. J Immunol 1998; 161: 4467-4471.
7. Albert ME, Sauter B, Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 1998; 392: 86-89.
8. Henry F, Bretaudeau L, Barbieux I, Meflah K, Gregoire M. Induction of antigen presentation by macrophages after phagocytosis of tumour apoptotic cells. Res Immunol 1998; 149: 673-679.
9. Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. Blood 1975; 46: 219-234.
10. Idestrom K, Kimby E, Bjorkholm M, Mellstedt H, Engstedt L, Gahrton G. Treatment of chronic lymphocytic leukaemia and well-differentiated lymphocytic lymphoma with continuous low-or intermittent high-dose prednimustine versus chlorambucil/prednisolone. Eur J Cancer Clin Oncol 1982; 18: 1117-1123.
11. Avila-Carino J, Lewin N, Yamamoto K, Tomita Y, Mellstedt H, Brodin B. EBV infection of B-CLL cells in vitro potentiates their allostimulatory capacity if accompanied by acquisition of the activated phenotype. Int J Cancer 1994; 58: 678-685.
12. Boyum A. Separation of lymphocytes, lymphocyte subgroups and monocytes: a review. Lymphology 1977; 10: 71-76.
13. Rezvany MR, Jeddi-Tehrani M, Biberfeld P, Soderlund J, Mellstedt H, Osterborg A. Dendritic cells in patients with non-progressive B-chronic lymphocytic leukaemia have a normal functional capability but abnormal cytokine pattern. Br J Haematol 2001; 115: 263-271.
14. + NK-T cells in whole blood. Cytometry 2000; 39: 72-78.
15. Rezvany MR, Jeddi-Tehrani M, Rabbani H, Ruden U, Hammarstrom L, Osterborg A. Autologous T lymphocytes recognize the tumour-derived immunoglobulin VH-CDR3 region in patients with B-cell chronic lymphocytic leukaemia. Br J Haematol 2000b; 111: 230-238.
16. Gong J, Nikrui N, Chen D, Koido S, Wu Z, Tanaka Y. Fusions of human ovarian carcinoma cells with autologous or allogeneic dendritic cells induce antitumor immunity. J Immunol 2000; 165: 1705-1711.
17. Comby E, Andre I, Troussard X, Lebrun E, Sola B, Ballet JJ. In vitro evaluation of B-CLL cells apoptotic responses to irradiation. Leukaemia Lymphoma 1999; 34: 159-166.
18. Osterborg A, Yi Q, Henriksson L, Fagerberg J, Bergenbrant S, Jeddi-Tehrani M. Idiotype immunization combined with granulocyte-macrophage colony-stimulating factor in myeloma patients induced type I, major histocompatibility complex-restricted, CD8-and CD4-specific T-cell responses. Blood 1998; 91: 2459-2466.
19. Buhmann R, Nolte A, Westhaus D, Emmerich B, Hallek M. CD40-activated B-cell chronic lymphocytic leukemia cells for tumor immunotherapy: stimulation of allogeneic versus autologous T-cells generates different types of effector cells. Blood 1999; 93: 1992-2002.
20. Kato K, Cantwell MJ, Sharma S, Kipps TJ. Gene transfer of CD40-ligand induces autologous immune recognition of chronic lymphocytic leukemia B cells. J Clin Invest 1998; 101: 1133-1141.
21. Fagerberg J, Yi Q, Gigliotti D, Harmenberg U, Ruden U, Persson B. T-cell-epitope mapping of the idiotypic monoclonal IgG heavy and light chains in multiple myeloma. Int J Cancer 1999; 80: 671-680.
22. Wen YJ, Lim SH. T-cells recognize the VH complementarity-determining region 3 of the idiotypic protein of B cell non-Hodgkin's lymphoma. Eur J Immunol 1997; 27: 1043-1047.
23. Wen YJ, Lim SH. In vivo immune responses to idiotypic VH complementarity-determining region 3 peptide vaccination in B-cell non-Hodgkin's lymphoma. Br J Haematol 1998; 103: 663-668.
24. Hoffmann TK, Meidenbauer N, Dworacki G, Kanaya H, Whiteside TL. Generation of tumor-specific T-lymphocytes by cross-priming with human dendritic cells ingesting apoptotic tumor cells. Cancer Res 2000; 60: 3542-3549.
25. Henry F, Boisteau O, Bretaudeau L, Lieubeau B, Meflah K, Gregoire M. Antigen-presenting cells that phagocytose apoptotic tumor-derived cells are potent tumor vaccines. Cancer Res 1999; 59: 3329-3332.
26. Inaba K, Turley S, Yamaide F, Iyoda T, Mahnke K, Inaba M. Efficient presentation of phagocytosed cellular fragments on the major histocompatibility complex class II products of dendritic cells. J Exp Med 1998; 188: 2163-2173.
27. Chen Z, Moyana T, Saxena A, Warrington R, Jia Z, Xiang J. Efficient antitumor immunity derived from maturation of dendritic cells that had phagocytosed apoptotic/necrotic tumor cells. Int J Cancer 2001; 93: 539-548.
28. Gong J, Avigan D, Chen D, Wu Z, Koido S, Kashiwaba M. Activation of antitumor cytotoxic T lymphocytes by fusions of human dendritic cells and breast carcinoma cells. Proc Natl Acad Sci USA 2000; 97: 2715-2718.
29. Schnurr M, Scholz C, Rothenfusser S, Galambos P, Dauer M, Robe J. Apoptotic pancreatic tumor cells are superior to cell lysates in promoting cross-priming of cytotoxic T-cells and activate NK and gammadelta T-cells. Cancer Res 2002; 62: 2347-2352.
30. Li JLMH, Franek KJ, Burgin KE, Wagner TE, Wei Y. Purified hybrid cells from dendritic cell and tumor cell fusions are superior activators of antitumor immunity. Cancer Immunol Immunother 2001; 50: 445-455.
31. Speidel K, Osen W, Faath S, Hilgert I, Obst R, Braspenning J. Priming of cytotoxic T lymphocytes by five heat-aggregated antigens in vivo: conditions, efficiency, and relation to antibody responses. Eur J Immunol 1997; 27: 2391-2399.
32. Kneitz C, Goller M, Wilhelm M, Mehringer C, Wohlleben G, Schimpl A. Inhibition of T-cell/B-cell interaction by B-CLL cells. Leukemia 1999; 13: 98-104.